• P-ISSN 0973-7200 E-ISSN 2454-8405
  • Follow us

Journal of Pharmaceutical Research

Article

Study on Prescribing Pattern of Proton Pump Inhibitors
  • VIEWS 113
  • PDF 49

Journal of Pharmaceutical Research

DOI: 10.18579/jopcr/v18.1.irene

Year: 2019, Volume: 18, Issue: 1, Pages: 1-6

Original Article

Study on Prescribing Pattern of Proton Pump Inhibitors

Ierne Maria Korah1, Jemi Elza Varkey1, Nayana Manjally1, Shaik Kaleem Basha1, R Rajeshwari1,∗, M S Krishnamurthy2

1Department of Pharmacy Practice, Krupanidhi College of Pharmacy, Carmelaram, Varthur Hobli, Bengaluru, Karnataka, India
2Department of General Medicine, MVJ Medical College and Research Hospital, Bangalore, Karnataka, India

 

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Objective: Proton pump inhibitors (PPIs) are still widely used despite increasing reports of adverse events. The objective of this study was to evaluate the pattern of prescription PPIs (proton pump inhibitors) and to monitor any potential drug interactions between these medications and other medications that were being taken concurrently. Methods: A prospective observational study was carried out at the MVJ Medical College and Research Centre in Bangalore over a six-month period. Findings: Totally, 204 prescriptions were assessed, and the majority of patients were aged 40 to 60 years (34%). The use of distribution-based dosage forms of proton pump inhibitors indicated that capsules were preferred over injections or tablets, with 88 capsules (43%) being utilised compared to 59 injections (29%) and 57 tablets (28 of the 204 prescriptions analysed, 113 (55%) consisting of proton pump inhibitor monotherapy, while 91 (45%) involved proton pump inhibitor combination therapy. Among the 204 prescriptions for PPI monotherapy, pantoprazole was used more frequently, accounting for 107 (98%) prescriptions. This trend was also observed with PPI combination therapy. Esomeprazole-domperidone 50 (53%) was the most commonly prescribed medication combination. Among the 41 prescriptions assessed, 30 (70%) involved drug-drug interactions with proton pump inhibitors (PPIs). The most frequently reported major drug interactions involved Pantoprazole and Methotrexate, whereas the most commonly reported moderate drug interactions involved Esomeprazole and Furosemide. We did not observe any adverse drug reactions (ADRs) and concluded that proton pump inhibitors (PPIs) are reasonably safe for short-term treatment. Novelty: The study of drug utilization could assess the prescription pattern of PPIs and identify noteworthy drug interactions in prescriptions. This report on the optimal utilization of proton pump inhibitors can be circulated to the concerned departments to improve patient outcomes.

Keywords: PPI; Prescribing patterns; DI; ADR

References

  1. Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, Maria D, et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert review of clinical pharmacology. 2018;11(11):1123–1134. Available from: https://doi.org/10.1080/17512433.2018.1531703
  2. Fossmark R, Martinsen TC, Waldum HL. Adverse effects of proton pump inhibitors-evidence and plausibility. International journal of molecular sciences. 2019;20(20):1–15. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829383/pdf/ijms-20-05203.pdf
  4. Halfdanarson OO, Pottegård A, Bjornsson ES, Lund SH, Ogmundsdottir MH, Steingrímsson E, et al. Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therapeutic advances in gastroenterology. 2018;11:1–11. Available from: https://doi.org/10.1177/1756284818777943
  5. Savarino V, Dulbecco P, Bortoli ND, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. European journal of internal medicine. 2017;37:19–24. Available from: https://doi.org/10.1016/j.ejim.2016.10.007
  6. Ksiądzyna D, Szeląg A, Paradowski L. Overuse of proton pump inhibitors. Pol Arch Med Wewn. 2015;125(4):289–298. Available from: https://www.mp.pl/paim/issue/article/2790/
  7. Madi L, Elhada AH, Alrawashdeh H, Ahmed A. Prescribing pattern of proton pump inhibitors in Qatar rehabilitation institute: A retrospective study. Journal of research in pharmacy practice. 2019;8(2):101–104. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636417/pdf/JRPP-8-101.pdf
  8. Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therapeutic advances in gastroenterology. 2012;5(4):219–251. Available from: https://doi.org/10.1177/1756283X12437358
  9. Bhosale MS, Jadhav NB, Adhav CV. Analysis of completeness and legibility of prescription orders at a tertiary care hospital. International Journal of Medicine & Public Health. 2013;3(3):180–183. Available from: https://www.ijmedph.org/Uploads/Volume3Issue3/IntJMedPubHealth-3-3-180.pdf
  10. Shahsavani N, Koneri DRR, Ramaiah B, Thomay SM. Assessment of prescribing pattern of proton pump inhibitor and histamine 2 receptor antagonist. Journal of Innovations in Pharmaceutical and Biological Sciences. 2016;3(3):13–22. Available from: https://jipbs.com/index.php/journal/article/view/157/133
  11. Tsoi KKF, Hirai HW, Sung JJ. Meta-analysis: comparison of oral vs. intravenous proton pump inhibitors in patients with peptic ulcer bleeding. Alimentary pharmacology & therapeutics. 2013;38(7):721–729. Available from: https://doi.org/10.1111/apt.12441
  13. Sheu BS, Kao AW, Cheng HC, Hunag SF, Chen TW, Lu CC. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Alimentary pharmacology & therapeutics. 2005;21(3):283–291. Available from: https://doi.org/10.1111/j.1365-2036.2005.02281.x
  14. Attwood SE, Ell C, Galmiche JP, Fiocca R, Hatlebakk JG, Hasselgren B, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Alimentary pharmacology & therapeutics. 2015;41(11):1–13. Available from: https://doi.org/10.1111/apt.13194
  15. Akram F, Huang Y, Lim V, Huggan PJ, Merchant RA. Proton pump inhibitors: are we still prescribing them without valid indications. The Australasian Medical Journal. 2014;7(11):465–470. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259212/pdf/AMJ-07-465.pdf

Copyright

© 2019 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/) 

  • 21 September 2024

Year: 2019, Volume: 18, Issue: 1


More articles

DON'T MISS OUT!

Subscribe now for latest articles and news.